The Protocol Library

Retatrutide vs Tirzepatide vs Semaglutide: Triple-Agonist Head-to-Head (2026)

Retatrutide vs tirzepatide vs semaglutide compared: receptor targets, trial weight-loss data, side effects, cost, and 2026 FDA status. Educational, evidence-based.

16 min

Retatrutide Weight Loss Results 2026: TRIUMPH-1 Data Explained

Retatrutide's Phase 3 TRIUMPH-1 trial reported up to 28.3% weight loss at 80 weeks. Here's what the 2026 data show, plus FDA status and safety.

10 min

Oral GLP-1s Explained: Wegovy Pill, Orforglipron, Rybelsus

Oral GLP-1s explained: how the Wegovy pill, orforglipron (Foundayo), and Rybelsus differ in dose, evidence, and FDA status. Educational, evidence-based guide.

12 min

Oral vs Injectable GLP-1: Which Loses More Weight?

Injectable GLP-1s like tirzepatide lead head-to-head trials, but oral semaglutide 25 mg now rivals weekly injections. A 2026 evidence-based comparison.

19 min

Survodutide for MASH: What to Know

Survodutide is an investigational glucagon/GLP-1 dual agonist studied for MASH. See phase 2 liver and fibrosis data, safety, dosing context, and FDA status.

12 min

TB-500 & the FDA: What the July 2026 PCAC Review Means

TB-500 (thymosin beta-4 fragment) won a favorable FDA Pharmacy Compounding Advisory Committee vote on July 23, 2026. Here's the regulatory status and the science.

11 min

Peptide Laws by State: US Legality Guide (2026)

How peptide laws work across all 50 US states in 2026: federal FDA 503A rules, the July 2026 PCAC vote, prescription requirements, and what varies locally.

13 min

Semaglutide Side Effects: The Definitive Guide

Semaglutide side effects explained: nausea, vomiting, diarrhea rates from FDA trials, the thyroid boxed warning, gallbladder and pancreatitis risk, and red flags.

12 min

GLP-1 Cost Comparison 2026: Ozempic vs Wegovy vs Compounded vs Oral

A 2026 GLP-1 cost comparison: Ozempic, Wegovy, compounded semaglutide, and the new oral Wegovy pill — list prices, cash-pay programs, and the post-shortage legal status.

11 min